Crescera Capital

Crescera Capital is a major Brazilian private equity firm headquartered in Rio de Janeiro with a long track record of consolidating healthcare and education markets, deploying $25M+ growth cheques into mature platforms with audited financials, durable EBITDA, and clear consolidation logic. The firm’s healthcare exposure spans care delivery, tech-enabled services, pharma, and selectively health IT software, with a preference for control or significant minority positions. For founders, Crescera is best understood as a PE consolidator rather than a venture growth investor, and is the right partner if you are running a $30M+ revenue Brazilian healthcare platform with a clear roll-up pipeline or specialty consolidation thesis. AI focus is not a stated priority and the firm’s value-add is operational and financial engineering rather than technology curve bets. Founders running early-stage digital health, software-only plays without depth, or pre-revenue plays should not approach. The cleanest entry path is via a Brazilian sell-side banker (BTG Pactual, Itau BBA, Bradesco BBI), a Crescera portfolio CEO, or a Big Four healthcare deals partner. In the pitch, lead with audited EBITDA, segment-level unit economics, regulatory and licensing posture, governance maturity, and a clear consolidation pipeline; come prepared to discuss management equity, board composition, and exit pathways through IPO or strategic sale. Caveats: as a PE firm, Crescera will price discipline and underwriting and term sheets carry standard PE governance terms including ratchets, drag-along, and management commitments. Brazilian macro and FX risk, plus payer dynamics across SUS and a consolidated private insurance market, will be probed thoroughly. Cycle times are months and the firm prefers proprietary processes. Founders should be realistic about valuation discipline and exit horizons (5-7 years) given the limited number of strategic acquirers in Brazilian healthcare.